Table 1.
Promising targets and molecules in novel T-ALL therapies.
| Target | Molecules | References |
|---|---|---|
| NOTCH signaling pathway | GSIs: γ-secretase inhibitors | [2,20,35,41,42] |
| ADAM10 and CAD204520 SERCA inhibitors | ||
| SAHM1: α-helical peptide | ||
| OMP-52M51: monoclonal antibody | ||
| CDK4/6 kinases | palbociclib | [7,22] |
| ribociclib | ||
| IL-7R/JAK/STAT signaling pathway | ruxolitinib | [2,14,42,45,46] |
| tofacitinib | ||
| PI3K/Akt/mTOR signaling pathway | everolimus | [14,22,42] |
| temsirolimus | ||
| ABL kinase | imatinib | [2,22,42] |
| dasatinib | ||
| nilotinib | ||
| BCL-2 protein | venetoclax | [49,50,51] |
| navitoclax | ||
| CD5, CD7 | CD7, CD5, and CD1a- targeted CAR T-cells | [1,61,62,63] |
| CD38 | daratumumab | [22,64] |